Epidemiological features and mechanism of coronavirus disease 2019 in children
DENG Quan-Min, LIANG Ping, LIU Han-Min
Department of Pediatrics, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu 610041, China
Abstract Compared with adults, children tend to have lower incidence rate, hospitalization rate, and mortality rate of coronavirus disease 2019 (COVID-19), while the cause of such age-based differences in disease severity remains unclear. An investigation of pathogenesis in children may help to analyze the therapies for the high-risk population. Human angiotensin-converting enzyme Ⅱ is the main receptor of severe acute respiratory syndrome coronavirus 2 and can limit pulmonary capillary leakage and inflammation mediated by angiotensin 2 and exert a protective effect against acute lung injury. Its expression decreases with age. Regular vaccination and frequent upper respiratory virus infection in children can lead to regular immune activation, and its combination with strong innate immunity can help to achieve virus clearance in the early stage of infection in children with COVID-19. Meanwhile, there are strong regeneration and repair abilities of alveolar epithelial cells in children, which may help with the early recovery of infection. In addition, risk factors, such as underlying cardiopulmonary diseases, obesity, and smoking, are relatively uncommon in children. Social factors, including home quarantine and timely closure of schools, may help to reduce the infection rate in children. However, children with immunodeficiency are a high-risk population and should be closely monitored. Further studies are needed to investigate the immune and protection mechanisms against COVID-19 in children.
Wu ZY, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019(COVID-19) outbreak in China:summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention[J]. JAMA, 2020, 323(13):1239-1242.
[4]
Salje H, Tran Kiem C, Lefrancq N, et al. Estimating the burden of SARS-CoV-2 in France[J]. Science, 2020, 369(6500):208-211.
[5]
Leidman E, Duca LM, Omura JD, et al. COVID-19 trends among persons aged 0-24 years-United States, March 1-December 12, 2020[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(3):88-94.
[6]
Center for Disease Control and Prevention. Risk for COVID-19 infection, hospitalization, and death by age group[EB/OL]. (2021-02-18)[2021-03-18]. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html.
[7]
Lee PI, Hu YL, Chen PY, et al. Are children less susceptible to COVID-19?[J]. J Microbiol Immunol Infect, 2020, 53(3):371-372.
[8]
Lu RJ, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J]. Lancet, 2020, 395(10224):565-574.
[9]
Gu HJ, Xie ZD, Li TL, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus[J]. Sci Rep, 2016, 6:19840.
[10]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2):271-280.e8.
[11]
Song RF, Preston G, Yosypiv IV. Ontogeny of angiotensin-converting enzyme 2[J]. Pediatr Res, 2012, 71(1):13-19.
[12]
Wang DW, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 323(11):1061-1069.
[13]
Liu WD, Chang SY, Wang JT, et al. Prolonged virus shedding even after seroconversion in a patient with COVID-19[J]. J Infect, 2020, 81(2):318-356.
[14]
To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2:an observational cohort study[J]. Lancet Infect Dis, 2020, 20(5):565-574.
[15]
Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019[J]. Nature, 2020, 581(7809):465-469.
[16]
Liu W, Tang F, Fontanet A, et al. Long-term SARS coronavirus excretion from patient cohort, China[J]. Emerg Infect Dis, 2004, 10(10):1841-1843.
[17]
van der Vries E, Stittelaar KJ, van Amerongen G, et al. Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets[J]. PLoS Pathog, 2013, 9(5):e1003343.
[18]
Guo JY, Huang Z, Lin L, et al. Coronavirus disease 2019(COVID-19) and cardiovascular disease:a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection[J]. J Am Heart Assoc, 2020, 9(7):e016219.
[19]
de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS:recent insights into emerging coronaviruses[J]. Nat Rev Microbiol, 2016, 14(8):523-534.
[20]
Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure[J]. Nature, 2005, 436(7047):112-116.
[21]
Liu Y, Yan LM, Wan LG, et al. Viral dynamics in mild and severe cases of COVID-19[J]. Lancet Infect Dis, 2020, 20(6):656-657.
[22]
Zou Z, Yan YW, Shu YL, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections[J]. Nat Commun, 2014, 5:3594.
[23]
Xie XD, Chen JZ, Wang XX, et al. Age- and gender-related difference of ACE2 expression in rat lung[J]. Life Sci, 2006, 78(19):2166-2171.
[24]
Liu YX, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury[J]. Sci China Life Sci, 2020, 63(3):364-374.
[25]
Zou LR, Feng R, Huang MX, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients[J]. N Engl J Med, 2020, 382(12):1177-1179.
[26]
Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223):497-506.
[27]
Tan MK, Liu YX, Zhou RP, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China[J]. Immunology, 2020, 160(3):261-268.
[28]
Qin C, Zhou LQ, Hu ZW, et al. Dysregulation of immune response in patients with coronavirus 2019(COVID-19) in Wuhan, China[J]. Clin Infect Dis, 2020, 71(15):762-768.
[29]
Lu XX, Zhang LQ, Du H, et al. SARS-CoV-2 infection in children[J]. N Engl J Med, 2020, 382(17):1663-1665.
[30]
Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role in health and disease[J]. Nat Rev Immunol, 2020, 20(6):375-388.
[31]
Yao YS, Jeyanathan M, Haddadi S, et al. Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity[J]. Cell, 2018, 175(6):1634-1650.e17.
[32]
Akkoc T, Aydogan M, Yildiz A, et al. Neonatal BCG vaccination induces IL-10 production by CD4+CD25+ T cells[J]. Pediatr Allergy Immunol, 2010, 21(7):1059-1063.
[33]
Kleen TO, Galdon AA, MacDonald AS, et al. Mitigating coronavirus induced dysfunctional immunity for at-risk populations in COVID-19:trained immunity, BCG and "new old friends"[J]. Front Immunol, 2020, 11:2059.
[34]
Sankoh O, Welaga P, Debpuur C, et al. The non-specific effects of vaccines and other childhood interventions:the contribution of INDEPTH Health and Demographic Surveillance Systems[J]. Int J Epidemiol, 2014, 43(3):645-653.
[35]
Teran R, Mitre E, Vaca M, et al. Immune system development during early childhood in tropical Latin America:evidence for the age-dependent down regulation of the innate immune response[J]. Clin Immunol, 2011, 138(3):299-310.
[36]
Pou C, Nkulikiyimfura D, Henckel E, et al. The repertoire of maternal anti-viral antibodies in human newborns[J]. Nat Med, 2019, 25(4):591-596.
[37]
Oh SJ, Lee JK, Shin OS. Aging and the immune system:the impact of immunosenescence on viral infection, immunity and vaccine immunogenicity[J]. Immune Netw, 2019, 19(6):e37.
[38]
Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age[J]. Proc Biol Sci, 2015, 282(1821):20143085.
[39]
Cameron MJ, Ran L, Xu LL, et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome[J]. J Virol, 2007, 81(16):8692-8706.
[40]
Navarro S, Driscoll B. Regeneration of the aging lung:a mini-review[J]. Gerontology, 2017, 63(3):270-280.
[41]
Yin L, Zheng DH, Limmon GV, et al. Aging exacerbates damage and delays repair of alveolar epithelia following influenza viral pneumonia[J]. Respir Res, 2014, 15(1):116.
[42]
Yazicioglu T, Mühlfeld C, Autilio C, et al. Aging impairs alveolar epithelial type Ⅱ cell function in acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol, 2020, 319(5):L755-L769.
[43]
Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2[J]. Eur Respir J, 2020, 56(3):2002961.
[44]
Petrilli CM, Jones SN, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City[J]. 2020. DOI:10.1101/2020.04.08.20057794. Epub ahead of print.
[45]
Geoghegan S, Erviti A, Caballero MT, et al. Mortality due to respiratory syncytial virus. Burden and risk factors[J]. Am J Respir Crit Care Med, 2017, 195(1):96-103.
